Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRC 8200 in Type 2 Diabetes Mellitus
NCT00836940Phase 2Unknown
- Sponsor
- Glenmark Pharmaceuticals
- Start
- Jun 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of melogliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Glenmark Pharmaceuticals. Primary endpoint: Change from baseline in Hemoglobin A1c at 12 weeks. Status: unknown.
02
Drugs
melogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00836940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00836940.